The VERVE-102 base-editing trial marks an early but notable step toward one-time PCSK9 inactivation, achieving up to 62% LDL reduction in a phase 1b study of 35 adults with heterozygous familial hypercholesterolemia or premature coronary disease, per the New England Journal of Medicine report (Vafai et al., 2026). Unlike daily statins or PCSK9 monoclonal antibodies, this in vivo editing aims to replicate lifelong low-cholesterol phenotypes seen in loss-of-function carriers, with effects persisting to 18 months in follow-up. Yet the small, industry-sponsored sample (Verve Therapeutics, now under Eli Lilly) lacks randomization and long-term hard endpoints, classifying it as observational-grade safety data rather than confirmatory efficacy. Prior work on PCSK9 inhibition, including the FOURIER trial (Sabatine et al., NEJM 2017, n=27,564), showed cardiovascular event reductions scale with LDL lowering, but real-world adherence drops below 50% within a year; a durable edit could shift population-level prevention if off-target editing and equitable access are resolved. Coverage often overlooks these durability questions and potential cost barriers exceeding current injectables. Related evidence from the earlier VERVE-101 program highlighted transient liver signals, underscoring the need for extended monitoring beyond 18 months.